Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial.

Differential prognostic effect of systemic inflammation in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial. Cancer. 2022 08 15; 128(16):3067-3079.

View in: PubMed

subject areas

B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung
Cell-Free Nucleic Acids
DNA Helicases
ErbB Receptors
Humans
Immunologic Factors
Immunotherapy
Inflammation
Kelch-Like ECH-Associated Protein 1
Lung Neoplasms
Male
NF-E2-Related Factor 2
Nuclear Proteins
Prognosis
Proto-Oncogene Proteins p21(ras)
Transcription Factors

authors with profiles

Abdulrafeh Naqash